Revenue: As of FY2025 Q1, the actual value is USD 1.9 K.

EPS: As of FY2025 Q1, the actual value is USD -1.58.

Segment Revenue

• Revenue: $2,000 for the three months ended July 31, 2025, compared to $0 for the same period in 2024.

Operational Metrics

• Net Loss: - $2,054,994 for the three months ended July 31, 2025, compared to - $2,051,689 for the same period in 2024.
• Gross Margin: $1,140 for the three months ended July 31, 2025, compared to $0 for the same period in 2024.
• Research and Development Expenses: $997,206 for the three months ended July 31, 2025, compared to $1,224,931 for the same period in 2024.
• Selling, General and Administrative Expenses: $878,053 for the three months ended July 31, 2025, compared to $850,736 for the same period in 2024.
• Loss from Operations: - $1,874,119 for the three months ended July 31, 2025, compared to - $2,075,667 for the same period in 2024.
• Interest Expense: - $183,688 for the three months ended July 31, 2025, compared to - $22,526 for the same period in 2024.
• Other Income: $2,813 for the three months ended July 31, 2025, compared to $46,504 for the same period in 2024.

Cash Flow

• Net Cash Used in Operating Activities: - $1,953,367 for the three months ended July 31, 2025, compared to - $2,018,720 for the same period in 2024.
• Net Cash Used in Investing Activities: - $814 for the three months ended July 31, 2025, compared to - $833 for the same period in 2024.
• Net Cash Provided by Financing Activities: $3,648,314 for the three months ended July 31, 2025, compared to $551,683 for the same period in 2024.

Future Outlook and Strategy

• Core Business Focus: The company plans to continue investing in research and development to develop technology for new products and to seek regulatory clearance for the MyoVista wavECG and MyoVista Insights Cloud Platform.
• Non-Core Business: The company is exploring strategic partnerships and additional equity financing to support its operations and growth initiatives.
• Priority: The company aims to achieve FDA clearance for its products and to commercialize its AI-ECG algorithms, with a focus on expanding its market presence and improving its financial performance.